Skip to main content

OTCMKTS:KYKOF - Kyowa Kirin Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$30.00
+0.30 (1.20%)
1 month | 3 months | 12 months
Get New Kyowa Kirin Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KYKOF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KYKOF

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Kyowa Kirin in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $30.00.

Buy

The current consensus among 2 investment analysts is to buy stock in Kyowa Kirin. This rating has held steady since March 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/23/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/21/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/21/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/19/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/17/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/15/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/16/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/16/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/31/2021JPMorgan Chase & Co.Initiated CoverageOverweight
i
2/18/2021Daiwa Capital MarketsDowngradeOutperform ➝ Neutral
i
12/9/2019Jefferies Financial GroupInitiated CoverageBuy
i
(Data available from 5/16/2016 forward)
Kyowa Kirin logo
Kyowa Kirin Co., Ltd., a specialty pharmaceutical company, manufactures and markets pharmaceuticals focused on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; GRAN, a human colony-stimulating factor; and G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia. The company's products also comprise LEUNASE for acute lymphoblastic leukemia; Mitomycin-C, an anticancer antibiotic; Moventig, an oral once daily peripherally acting mu-opioid receptor antagonist for the treatment of opioid induced constipation in adult patients; PecFent, a nasally administrated spray; POTELIGEO, a humanized monoclonal antibody that targets CC chemokine receptor 4; and REGPARA, an agent for the treatment of secondary hyperparathyroidism. In addition, it offers Romiplate/Nplate, a genetically recombinant protein, which stimulates platelet production through the stimulation of thrombopoietin receptors; and SANCUSO for the treatment of nausea and vomiting. Kyowa Kirin Co., Ltd. has strategic research alliance with Harvard University. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was founded in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.
Read More

Today's Range

Now: $30.00
$30.00
$30.00

50 Day Range

MA: $29.57
$29.45
$30.00

52 Week Range

Now: $30.00
$24.50
$30.00

Volume

N/A

Average Volume

660 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Kyowa Kirin?

The following equities research analysts have issued research reports on Kyowa Kirin in the last year: Daiwa Capital Markets, and JPMorgan Chase & Co..
View the latest analyst ratings for KYKOF.

What is the current price target for Kyowa Kirin?

0 Wall Street analysts have set twelve-month price targets for Kyowa Kirin in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Kyowa Kirin in the next year.
View the latest price targets for KYKOF.

What is the current consensus analyst rating for Kyowa Kirin?

Kyowa Kirin currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe KYKOF will outperform the market and that investors should add to their positions of Kyowa Kirin.
View the latest ratings for KYKOF.

What other companies compete with Kyowa Kirin?

Other companies that are similar to Kyowa Kirin include (BUX), (CHV), (CSI), (PHGI), (PREV), (THCX.V), 12144, 1300SMILES, 138267 (COM.TO), 17031, 1933 Industries, 28896, 31444, 438280 and 4DMedical.

How do I contact Kyowa Kirin's investor relations team?

The company's listed phone number is 81 3 5205 7200. The official website for Kyowa Kirin is www.kyowakirin.com.